Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.

@article{Belaiche2001TherapeuticDM,
  title={Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.},
  author={Jacques Belaiche and J. P. Desager and Yves Horsmans and Edouard V Louis},
  journal={Scandinavian journal of gastroenterology},
  year={2001},
  volume={36 1},
  pages={71-6}
}
BACKGROUND 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD). The immunosuppressive properties of AZA/6-MP are mediated by the intracellular metabolism of 6-MP into its active metabolites, 6-thioguanine nucleotides (6TGN) and 6methylmercaptopurine (6-MMP). Preliminary studies have suggested that the red blood cell concentration of 6TGN (RBC 6TGN) is a potential guide to therapy. The aims of the study were to evaluate the RBC… CONTINUE READING
32 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD [abstract

  • C Cuffari, M Picco, S Hunt, T. Bayless
  • Gastroenterology
  • 1999
Highly Influential
6 Excerpts

Dosage de la 6-mercaptopurine et étude des sous-populations lymphocytaires sanguines au cours du traitement par l'azathioprine dans la maladie de Crohn

  • S Cattan, M Lémann, F Thuillier, D Bengoufa, C Rabian, Y Ngo
  • Gastroenterol Clin Biol
  • 1998
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…